Retinoblastoma-Pipeline Review, H1 2015

Retinoblastoma-Pipeline Review, H1 2015

  • Products Id :- GMDHC6762IDB
  • |
  • Pages: 57
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Retinoblastoma-Pipeline Review, H1 2015


Global Markets Direct's, 'Retinoblastoma-Pipeline Review, H1 2015', provides an overview of the Retinoblastoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Retinoblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinoblastoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Retinoblastoma

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Retinoblastoma and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Retinoblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Retinoblastoma pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Retinoblastoma

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Retinoblastoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Retinoblastoma Overview 6

Therapeutics Development 7

Pipeline Products for Retinoblastoma-Overview 7

Pipeline Products for Retinoblastoma-Comparative Analysis 8

Retinoblastoma-Therapeutics under Development by Companies 9

Retinoblastoma-Therapeutics under Investigation by Universities/Institutes 10

Retinoblastoma-Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Retinoblastoma-Products under Development by Companies 13

Retinoblastoma-Products under Investigation by Universities/Institutes 14

Retinoblastoma-Companies Involved in Therapeutics Development 15

BioLineRx, Ltd. 15

Cellceutix Corporation 16

Icon Bioscience, Inc. 17

Neotropix, Inc. 18

Recombio S.L 19

RXi Pharmaceuticals Corporation 20

Retinoblastoma-Therapeutics Assessment 21

Assessment by Monotherapy Products 21

Assessment by Target 22

Assessment by Mechanism of Action 24

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Drug Profiles 30

BL-8040-Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Kevetrin-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

melphalan-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

NTX-010-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

nutlin-3-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

racotumomab-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

RNAi Oligonucleotide for Retinoblastoma-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Retinoblastoma-Recent Pipeline Updates 42

Retinoblastoma-Dormant Projects 53

Retinoblastoma-Product Development Milestones 54

Featured News & Press Releases 54

Mar 08, 2013: Cellceutix Announces Positive Preclinical Trial Data Of Kevetrin In Retinoblastoma 54

Jan 03, 2013: Icon's Melphalan Intraocular Injection Receives US Orphan Drug Designation For Treatment Of Retinoblastoma 54

Appendix 56

Methodology 56

Coverage 56

Secondary Research 56

Primary Research 56

Expert Panel Validation 56

Contact Us 56

Disclaimer 57

List of Tables

Number of Products under Development for Retinoblastoma, H1 2015 7

Number of Products under Development for Retinoblastoma-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Number of Products under Investigation by Universities/Institutes, H1 2015 10

Comparative Analysis by Clinical Stage Development, H1 2015 11

Comparative Analysis by Early Stage Development, H1 2015 12

Products under Development by Companies, H1 2015 13

Products under Investigation by Universities/Institutes, H1 2015 14

Retinoblastoma-Pipeline by BioLineRx, Ltd., H1 2015 15

Retinoblastoma-Pipeline by Cellceutix Corporation, H1 2015 16

Retinoblastoma-Pipeline by Icon Bioscience, Inc., H1 2015 17

Retinoblastoma-Pipeline by Neotropix, Inc., H1 2015 18

Retinoblastoma-Pipeline by Recombio S.L, H1 2015 19

Retinoblastoma-Pipeline by RXi Pharmaceuticals Corporation, H1 2015 20

Assessment by Monotherapy Products, H1 2015 21

Number of Products by Stage and Target, H1 2015 23

Number of Products by Stage and Mechanism of Action, H1 2015 25

Number of Products by Stage and Route of Administration, H1 2015 27

Number of Products by Stage and Molecule Type, H1 2015 29

Retinoblastoma Therapeutics-Recent Pipeline Updates, H1 2015 42

Retinoblastoma-Dormant Projects, H1 2015 53

List of Figures

Number of Products under Development for Retinoblastoma, H1 2015 7

Number of Products under Development for Retinoblastoma-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Comparative Analysis by Early Stage Products, H1 2015 12

Assessment by Monotherapy Products, H1 2015 21

Number of Products by Top 10 Targets, H1 2015 22

Number of Products by Stage and Top 10 Targets, H1 2015 23

Number of Products by Top 10 Mechanism of Actions, H1 2015 24

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 25

Number of Products by Top 10 Routes of Administration, H1 2015 26

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 27

Number of Products by Top 10 Molecule Types, H1 2015 28

Number of Products by Stage and Top 10 Molecule Types, H1 2015 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@]

BioLineRx, Ltd.

Cellceutix Corporation

Icon Bioscience, Inc.

Neotropix, Inc.

Recombio S.L

RXi Pharmaceuticals Corporation

Retinoblastoma Therapeutic Products under Development, Key Players in Retinoblastoma Therapeutics, Retinoblastoma Pipeline Overview, Retinoblastoma Pipeline, Retinoblastoma Pipeline Assessment

select a license

Single User License
USD 2000 INR 130000
Site License
USD 4000 INR 260000
Corporate User License
USD 6000 INR 390000



The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

query [@]